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Abstract
Background: OnkoNetwork is a recently established integrated care model with a personalized pathway system to
manage patients with first suspect of a solid tumour in secondary care, that evolved as a regional initiative in
Hungary. The primary aim of OnkoNetwork is the improvement of clinical outcomes via timely access to quality
assured and defragmented healthcare services. The Horizon 2020 funded SELFIE project has selected OnkoNetwork
for in-depth qualitative and quantitative evaluation. The aim of this study was to provide a qualitative evaluation of
OnkoNetwork along the six components of the SELFIE conceptual framework: 1) service delivery, 2) leadership and
governance, 3) workforce, 4) financing, 5) technologies and medical products, and 6) information and research.
Methods: Analysis of published and grey programme documentation, followed by 20 semi-structured interviews
with representatives of programme initiators, general and financial managers, involved physicians and non-
physician professionals, patients and their informal caregivers. Transcripts of all interviews were analysed by
Mayring’s content analysis method by two independent researchers.
Results: This study yielded the first comprehensive description of the programme. OnkoNetwork is a blue dahila in
Central and Eastern Europe, providing timely and quality-assured healthcare services for the target patients by
personalized patient path monitoring and management in a financially sustainable manner without macro-level
financing of its operation. Innovative professional roles were implemented for non-physicians and physicians, and a
supporting information technology application was developed.
Conclusions: This paper provides a systematic description of OnkoNetwork on the six components of the SELFIE
conceptual framework for integrated care in multimorbidity to understand how and why OnkoNetwork was
implemented and cares (better) for its patients. Because integrated care models are designed and adjusted to their
specific local needs and context, those few successful and sustainable models that were established in Central and
Eastern European countries represent important benchmarks for other initiatives in this region. Experience with
OnkoNetwork during its planning, implementation and operation including the description of key success factors
and barriers as perceived by various stakeholder groups, may support the development of further integrated care
models especially in countries with similar economic status and healthcare settings.
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Background
Prevalence of multi-morbidity is rapidly increasing in
Western populations. As opposed to fragmented and
single disease focused health care provision, the need for
personalized integrated care is more and more recog-
nized [1–3]. A recently published new framework on in-
tegrated care for multi-morbidity organised elements of
integrated care that had previously been reported to
contribute to its effectiveness into the six WHO compo-
nents of health systems, thus providing a model for a
system-level approach [1]. The establishment of this
framework was an important initial achievement of the
Horizon2020 funded SELFIE project (Table 1 near here).
This conceptual framework guided the detailed qualita-
tive description and the currently ongoing quantitative
evaluation of 17 selected integrated chronic care models
for persons with multi-morbidity, in 8 European Union
Member States participating in SELFIE, including Austria,
Croatia, Germany, Hungary, the Netherlands (coordinator
of SELFIE), Norway, Spain, and the UK. A brief descrip-
tion of the challenges faced by the SELFIE project and
four other EU funded projects on integrated care for mul-
timorbid patients (SUSTAIN, ACT@Scale, SCIROCCO,
JA-CHRODIS/CHRODIS-PLUS) was given by Rutten-van
Mölken et al. [2]. This paper focuses on one of the Hun-
garian integrated care programmes analysed in SELFIE,
named OnkoNetwork.
OnkoNetwork is a recently established integrated care
model with a personalized care pathway to manage pa-
tients with first suspect of a solid tumour, that evolved as
a regional initiative to tackle severe coordination deficits
within the healthcare system in Hungary. OnkoNetwork
aims to improve clinical outcomes via timely access to
quality assured and defragmented healthcare provision.
This model was established in 2014 by the Móritz Kaposi
General Hospital in Somogy county, Hungary. To support
the documentation and management of individualised
care pathways, a tailor-made IT system was developed,
and new professional roles were established for both
non-physicians and physicians [4, 5]. Target patient
groups in OnkoNetwork have high rates of clinically rele-
vant comorbidities, which explains why the programme
was selected by the SELFIE consortium as one of the most
promising integrated care models for patients with
multi-morbidity in Hungary. OnkoNetwork focuses on
improving timely access to diagnosis and start of cancer
treatment because this is associated with improved patient
survival in many types of cancer e.g. in lung cancer [6, 7],
oral squamous cell cancer [8], head and neck squamous
cell carcinoma [9, 10], and breast cancer [11].
The aim of this paper is to give a systematic descrip-
tion of OnkoNetwork on the six components of the
SELFIE conceptual framework for integrated care in
multi-morbidity: 1) service delivery, 2) leadership and
governance, 3) workforce, 4) financing, 5) technologies
and medical products, and 6) information and research.
The full report of the qualitative study is available from
the SELFIE website (http://www.selfie2020.eu) as a thick
description [12]. This study can support the creation
and implementation of future individual care pathways,
especially in countries with similar healthcare systems
and economic status to Hungary.
Methods
Thick description
Thick description is a qualitative empirical approach intro-
duced by Gilbert Ryle [13] and exploited in the 1970s by Clif-
ford Geertz as a qualitative method to investigate implicit
social practices [14]. Geertz’ methodological and conceptual
work influenced empirical research in several disciplines [15],
and thick description became a well-established approach in
sociology including care practice research [16]. In brief, first
the “hard facts” about the investigated phenomenon are de-
scribed, then it is supplemented with “soft facts” answering
the “how” and “why” questions and allowing a deeper under-
standing of the operational practice. In the SELFIE project,
“hard” and “soft” facts were collected both from document
analysis and from stakeholder interviews.
Document analysis
The analysed documents included Hungarian language
publications on OnkoNetwork as identified via internet
searches in PubMed and Google, and internal documents
provided by the managers of OnkoNetwork (official docu-
ments of the programme and written correspondence).
Relevant data were extracted, including but not limited to
the scope and organisational structure of the programme
(e.g. official name, implementation milestones, aims, target
Table 1 About the SELFIE project
SELFIE (Sustainable int E grated chronic care mode L s for multi-
morbidity: delivery, FI nancing, and performanc E) is a Horizon2020
funded EU project that aims to contribute to the improvement of
person-centred care for persons with multi-morbidity by proposing
evidence-based, economically sustainable, integrated care programmes
that stimulate cooperation across health and social care and are sup-
ported by appropriate financing and payment schemes.
More specifically, SELFIE aims to:
• Develop a taxonomy of promising integrated care programmes for
persons with multi-morbidity
• Provide evidence-based advice on matching financing/payment
schemes with adequate incentives to implement integrated care
• Provide empirical evidence of the impact of promising integrated care
on a wide range of outcomes using Multi-Criteria Decision Analysis
• Develop implementation and change strategies tailored to different care
settings and contexts in Europe, especially Central and Eastern Europe
The SELFIE consortium includes eight organisations in the following
countries: the Netherlands (coordinator), Austria, Croatia, Germany,
Hungary, Norway, Spain, and the UK. www.selfie2020.eu [Grant
Agreement No 634288]. Accessed 20 Feb 2019.
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patients, service delivery, involved disciplines and profes-
sions, organizational form, and IT support tools).
Selection of interview participants
Altogether 20 interviews have been conducted with repre-
sentatives of the key stakeholder groups of OnkoNetwork:
one programme manager, two programme initiators (opin-
ion leaders that participated in initiating, conceptualising
and planning the programme), one financial expert of
programme funding, four physicians, eight non-physician
health care professionals of OnkoNetwork, two patients,
and two informal caregivers (family members of patients).
Since OnkoNetwork is without specific macro-level finan-
cial incentives or regulatory or policy support system, rep-
resentatives of the National Health Insurance Fund and
State Secretariat for Health at the Ministry of Human Cap-
acities were not considered as relevant stakeholders and
were not interviewed about their views on OnkoNetwork.
Selection of and proportions across these stakeholder
groups were guided and approved by the corresponding
work package leaders of the SELFIE consortium, in a pur-
posive rather than convenience-oriented manner; selection
of all interviewers preceded the start of analysis, therefore
deciding on stakeholder group proportions was not influ-
enced by saturation of information across interviews. From
the corresponding stakeholder groups, the interviewees
themselves were selected and invited by the OnkoNetwork
management team, based on their personal involvement in
OnkoNetwork related activities. For the patient and infor-
mal caregiver stakeholder groups, multimorbidity was also
a selection criterion. The number of interviewed physicians
and non-physicians was slightly higher than initially
planned (3 and 5, respectively), due to a few snowball par-
ticipants. None of the invited interview participants refused
to take part in this study.
Interviews
The interviews were conducted by two male employees
of Syreon Research Institute, the SELFIE research team
in Hungary (authors JGP and MCs), with MD, PhD and
with MSc credentials, respectively. All interviews were
conducted face-to-face without making field notes, with
voice recording, in Hungarian language. The 30- to
90-min interviews (median 60min) took place in the fa-
cilities of the Móritz Kaposi General Hospital at Kapos-
vár, in July 2016, in a quiet, light and door-separated
room without through traffic and equipped with a table
and chairs. Beyond the interviewee and the two inter-
viewers, no one else was present in the room during the
interviews, except for one interview where two family
members of the same patient arrived and preferred to be
interviewed together. The interviews were semi-structured.
Wording of the questions was guided by a written interview
protocol that determined the structure of the interviews,
and defined stakeholder group specific themes according to
the SELFIE conceptual framework (Table 2; the Interview
Protocol is provided in the Additional file 1). The inter-
view protocols were standardized across the SELFIE con-
sortium but were flexible enough to further discuss
important topics that came up during the interviews, due
to the semi-structured approach. The corresponding
Work Package leader provided personal training and de-
tailed guidance how to get prepared for the interviews.
Pilot interviews hence were not deemed necessary. In gen-
eral, all interview protocols were structured as follows:
first a brief introduction about SELFIE and objectives of
the interview were presented, followed by signing the in-
formed consent for recording (all invited interviewees
agreed to do so). The first research questions dealt with
the participant’s qualification and his/her role in Onko-
Network. Next questions covered specific topics of each
stakeholder group (Table 2). The last question was about
the interviewee’s perception on the most important
achievement of and the most important future challenge
for OnkoNetwork [12].
Interview protocols were not shared with the inter-
viewees. All participants were interviewed only once.
Interview analysis
Based on the audio recordings, interviews were tran-
scribed and analysed by Mayring’s content analysis
method [17], using the following steps of abductive in-
terpretation: selection of units for analysis; paraphrasing;
making short forms; and creating categories around
common themes when possible.
Short forms and category constructs were developed
by the two researchers who conducted the interviews, in
English language, in Microsoft Excel. Their findings were
Table 2 Key focus areas of the interviews by stakeholder
groups
Stakeholder groups Key focus areas of the interviews
Programme Manager Personal contribution to the programme;
Programme achievements in patient-centred
care
Programme Initiators Basic idea and the conceptual framework of
the programme
Financial experts /
payers
Considerations about the financing decision;
Experiences with the financing and payment
systems
Physicians Changes in physicians’ work practice due to
the programme
Non-physician
professionals
Personal description of last workday;
Experience with active participation of
patients
Informal caregivers Personal description of care work;
Personal involvement in the programme
Patients Personal description of care experience;
Personal experience in self-management
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pooled to reduce the risk of “blind spots” of a single ana-
lyst in the abstraction process. All recognised constructs
were assigned to one or more of the eight domains (pre-
specified by the SELFIE consortium) covering different
aspects of the evaluated programme, such as (i) imple-
mentation aims and history, (ii) delivery of care; (iii)
relationships with other care providers; (iv) role of informa-
tion and communication technology (ICT) applications; (v)
self-management interventions; (vi) new professional roles;
(vii) existing evidence on impact; and (viii) experience with
financing / payment schemes. Each paraphrase could be
analysed in multiple contexts, depending on the complexity
of its content. Because these domains covered the six com-
ponents of the SELFIE framework, the information gath-
ered in each domain was later assigned to one of SELFIE
framework components, except for implementation history
that corresponds to the framework as a whole. Finally, an
integrated description of the system components was de-
rived from the document and interview analysis, explicitly
contrasting the views of various stakeholder groups when
divergence was observed. Findings of the interview analysis
were presented to those interview participants who were
co-authors of the Thick Description and this manuscript;
all of them reviewed and approved the report findings with-
out substantial changes.
Quality assurance
To ensure the proper implementation of the selected
methodology in the description of all the 17 selected
models, the SELFIE work package leader provided other
SELFIE partners with detailed methodology guidance in
three waves. In the preparatory phase, written meth-
odological guidance materials were distributed to all
partners. Then a training course was offered to inter-
viewers and researchers directly involved in the thick
description process, before conducting the interviews.
Finally, the reports of the 17 thick descriptions were
reviewed by the work package (co)leaders to ensure
that their results were clearly presented and to harmon-
ise their structure. Reporting quality in the present
paper was cross-checked to comply with the consoli-
dated criteria for reporting qualitative studies using the
32-item COREQ checklist [18].
Results
Findings of the thick description of OnkoNetwork are
described along the six components of the SELFIE
framework (i.e. service delivery, leadership and govern-
ance, workforce, technologies and medical products, in-
formation and research, and financing), preceded by a
short description of its planning and implementation
history.
Implementation of OnkoNetwork
Planning phase
The idea of OnkoNetwork first came up in July 2014
when the Strategic Director of the Móritz Kaposi Gen-
eral Hospital set up a small interdisciplinary team to
understand the root causes of the unexpectedly high
cancer mortality in Hungary [19]. This county hospital is
responsible for the comprehensive oncology care of
about 500,000 inhabitants in Hungary, in close cooper-
ation with the Kaposvár University Health Center (re-
sponsible for CT, MR, PET CT, PET MR diagnostics and
also for radiotherapy), with outpatient cancer care de-
partments of the Hospital in other locations (Siófok,
Nagyatád, Marcali), and with a radiotherapy unit in
Mosdós [4]. The team looked for quantitative indicators
with high variability that could be controlled by the
above institutions and identified two parameters calling
for improvement. First, diagnostic delay in the centre
(time from the first presented suspect of cancer in the
medical system of the participating institutions to the
Tumour Board meeting with final diagnosis) was found
to be as long as 6months in many cases. Secondly, the
treatment initiation delay (time from final diagnosis to
the first treatment day) was also longer than the optimal
time window for many patients. To reduce these time
windows in the catchment area of the Hospital, a new
system to manage and optimise patient pathways was
proposed as a local initiative. The planning phase was
based on intensive teamwork involving both the hospital
management and the heads of all hospital departments
contributing to cancer diagnosis or treatment (listed on
Fig. 1). After repeated meetings and strategic discus-
sions, the ultimate objective of OnkoNetwork was
framed as “provision of timely and equitable access to
comprehensive and integrated oncology care”. Potential
economic benefits (such as a reduction in average treat-
ment costs) were not the primary focus in the planning
phase. OnkoNetwork was based on several principles.
First of all, quality assurance was facilitated by the devel-
opment and implementation of organ-specific, evidence
based clinical protocols. Secondly, tracking of each pa-
tient by an identified responsible physician had to be
made continuously to prevent patients from being lost
in the system. Thirdly, quantitative indicators were de-
fined: the target for a conclusive Tumour Board decision
on the proposed therapy was set at a maximum of 30
days of enrolment into OnkoNetwork, and thereafter the
treatment should be started within 14 days. To support
these principles, development of a new tailor-made IT
system was decided for real-time collection and moni-
toring of the clinical documentation of oncology patients
[4]. Given the volume and complexity of the existing
medical IT system of the Hospital, the realistic ambition
was to develop the new IT tool running in parallel with
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pre-existing medical IT applications, rather than as a re-
placement of them.
Implementation history
OnkoNetwork was implemented in a pre-planned change
management process. The first implementation step was
the development of organ-specific diagnostic algorithms:
available clinical protocols that typically contained a couple
of optional investigations to be selected along not fully ex-
plicit criteria were translated into organ-specific diagnostic
algorithms with standardized lists of all necessary investiga-
tions by the organs affected. Harmonized process descrip-
tions of hospital departments were also developed. After
consensus was achieved in these aspects, the development
of a customized IT application (OncoLogistic) was started,
in parallel with the thorough reorganization of teams and
harmonization of oncology care in all relevant departments
[4]. Since no relevant prior experience could be identified
in Hungary, the workflow description and the definition of
new professional roles were started from scratch, based on
thorough discussions involving all stakeholders. An Onko-
Network Office (see below) was established and OncoLo-
gistic functions were continuously revised and fine-tuned.
OnkoNetwork was officially launched in November 2015,
after a 1-month test period.
After this brief overview of the planning and imple-
mentation phases, the next sections describe the Onko-
Network model along each component of the SELFIE
framework.
Service delivery
Target population
The target population of OnkoNetwork consists of adult
(≥18 years) patients with new suspect or new diagnosis
of solid tumours (an ICD disease code starting with “C”
or “D”, except for haematology malignancies, and some
rare tumours that are referred to specialized national
centres) in the catchment area of the Kaposi Mór Gen-
eral Hospital at Kaposvár. This catchment area roughly
overlaps with Somogy county of Hungary with a 500,000
population, including patients visiting the Oncology out-
patient units of Municipal Hospitals at Nagyatád and
Siófok. Having chronic comorbidities is not an enrol-
ment criterion in OnkoNetwork, the most frequent
chronic comorbidities in the enrolled population are car-
diovascular diseases, hypertension, and diabetes occur-
ring in about 49, 26, and 11%, respectively. Diagnosis
and adequate treatment of comorbidities interfering with
cancer care are inevitable in many cancer patients, e.g.
pacemakers need to be switched off or removed during
high frequency ablation; patients receiving cardiotoxic
Fig. 1 Integration of healthcare service providers in OnkoNetwork. Modified from [4]
Pitter et al. BMC Health Services Research          (2019) 19:131 Page 5 of 13
chemotherapy require cardiologic control; or metformin
treatment of diabetic patients need to be discontinued be-
fore CT scan to avoid kidney damage, as a few examples.
The care processes
Patient enrolment OnkoNetwork offers priority in care,
personalized care pathways, and timely access to quality
assured healthcare services for enrolling patients upon
their first appearance in the hospital’s medical system.
At the entry visit, the OnkoNetwork care model is ex-
plained to the patient and the enrolment is offered upon
signing an informed consent form. Most of the invited
patients has decided to join OnkoNetwork so far.
Personalized diagnostic plans After filling in a stan-
dardized questionnaire on anamnesis, risk factors, co-
morbidities, and current medications, a responsible
physician is appointed to each enrolled patient. The
diagnostic plan is guided by organ- and disease-specific
protocols, and the responsible physician can deviate
from the diagnostic protocols only with specified and
documented reasons. Diagnostics and management of
comorbidities must also comply with timelines estab-
lished for cancer diagnostics and start of cancer therapy.
Coordination and documentation of diagnostic visits
Before the OnkoNetwork era, arrangement of diagnostic
visits was a huge burden for physicians with inefficient
phone calls and fighting for earlier dates. By the intro-
duction of OnkoNetwork and the declaration of priority
status for cancer patients, early dates are continuously
available and can be booked through a web application
or phone by non-physician staff members. The reduced
diagnostic time windows for OnkoNetwork patients
were not reported to have negative influence on waiting
times of other patients. Preferences of patients are taken
into account, e.g. when scheduling multiple diagnostic
visits on the same day to decrease unnecessary travel
costs and time. Documents for referral to further diag-
nostic tests are given to patients during their first visit,
in order to avoid repeated hospital visits merely to
organize the forthcoming diagnostic procedures.
Tumour board meeting The Tumour Board (also called
“Onkoteam” in Hungary) is a multidisciplinary board of
the Hospital consisting at least of a clinical oncologist, a
surgeon and a non-surgeon specialist of the affected
organ system, a (molecular) pathologist, a radiologist, a
radiotherapist, the patient’s treating physician, and a co-
ordinator of the team. The composition of this board is
defined by the law with the primary responsibility of
providing multidisciplinary personalized diagnostics and
treatment plans for cancer patients. Once all necessary
diagnostics are completed the case has to be referred to
the next Tumour Board meeting, within 30 days of enter-
ing OnkoNetwork [4, 5]. OnkoNetwork did not change
the composition or frequency of Tumour Board meetings
but smoothed its operation by validating the completeness
of patient documentation prior to the meeting and provid-
ing online access to diagnostic results at the meeting. Par-
ticipation of patients in the Tumour Board meetings is
exceptional, as it would not be technically feasible due to
time pressure on Tumour Board members. In a few days
after the Tumour Board meeting, the responsible phys-
ician informs patients about their treatment plans. In
many cases, alternative treatment options are discussed
with the patient who may accept, reject or occasionally
adapt the proposed treatment strategy.
Treatment and follow-up In OnkoNetwork, the agreed
cancer therapy must be initiated within 14 days after the
conclusive Tumour Board meeting. Any delay in refer-
ring a case to the Tumour Board, or in therapy initiation
must be justified by the responsible physician. To ensure
that patients are treated as agreed in the multidisciplin-
ary Tumour Board meeting, it is not allowed to start any
cancer therapy prior to the decision of the Tumour
Board. Nevertheless, clinical management of relevant co-
morbidities does not have to wait for the Tumour Board
decision. After the completion of acute interventions, a
follow-up Tumour Board meeting is scheduled, and
follow-up plans are made with regular control diagnos-
tics. Administrators at the OnkoNetwork Office trace
those patients who do not appear at these control visits
or who have delayed Tumour Board meetings.
Leadership and governance
The management of the Móritz Kaposi General Hospital
played a proactive and leading role in the conceptual de-
velopment, planning, and implementation of OnkoNet-
work. In the implementation phase the Hospital General
Director delegated the OnkoNetwork upper manage-
ment responsibility to the co-initiator Strategic Director
of the Hospital, who also acts as a professor at the
Kaposvár University Health Centre [4]. Note that most
OnkoNetwork activities are hosted by the Móritz Kaposi
General Hospital, which – as a county hospital – is
equipped to fulfil a leadership role in organizing health
care in the region and has a relatively centralized gov-
ernance structure, as opposed to medical centres of uni-
versities with greater independence of various clinics
and distinguished professors. The leadership team made
continuous efforts to achieve decisions by consensus at
interactive meetings, and any feedback was seriously con-
sidered in the implementation process. Program launch
was approved by the Board of Directors, and was an-
nounced by the General Director of the Hospital [4, 5].
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The organizational structure of OnkoNetwork, and its
core features are depicted in Figs. 1 and 2.
Fear of change and protection of status quo based on
individual or departmental incentives were noticeable
upon implementation. At initiation, many physicians
had to learn that they could not make decisions alone
anymore, and they had to work with other health care
professionals as a team in order to provide integrated
multidisciplinary care. The upper management success-
fully overcame the initial resistance by continuous
reinforcement of OnkoNetwork’s principles. OnkoNet-
work was implemented according to a change manage-
ment process with systematic amendments of work
descriptions. Education and training, written instructions
to all professionals, and learning by doing opportunities
in the test period also contributed to the successful im-
plementation. The availability of all necessary diagnostic
and treatment modalities for a complex oncology care
centre, as well as the underlying infrastructural develop-
ments and the consistent development strategy of the
hospital to provide cutting edge oncology care in the last
10–15 years were also strong success factors for Onko-
Network at Kaposvár.
Monitoring of OnkoNetwork operations is accom-
plished at multiple hierarchical levels, ranging from a
dedicated project office (OnkoNetwork Office) consist-
ing of 4 full-time administrators and an Office Manager,
through two supervisor physicians, to the top manage-
ment. The Strategic Director does not have to be in-
volved in OnkoNetwork operation on a daily basis but is
informed every week about all patients with delays. His
unique leadership position and strong commitment to
OnkoNetwork are important facilitators for implementa-
tion, permanent operation and future development of
the model. The Hospital General Director may also
intervene in the rare escalated cases, e.g. when noncom-
pliance is identified at a department level. Macro-level
approval or adjustment of the external legal framework
was not necessary, due to hospital autonomy.
Political support to OnkoNetwork by the central gov-
ernment was not visible for a long time. The programme
was first recognized by the Hungarian Health Economics
Association, which has been playing an important role in
the promotion of evidence based health policy [20]. Subse-
quently, the general media and patients with access prob-
lems in other regions acknowledged the potential benefits
of the programme. The opinion of other oncology centres
on OnkoNetwork in the region was initially negative, but
later they understood that it does not aim to compete for
their patients. Finally, the importance and benefits of
OnkoNetwork were recognized by the State Secretariat at
the Ministry of Human Capacities. The OnkoNetwork
team received an award from the Minister of Human Cap-
acities for their exemplary professional work in healthcare
in 2016. Scaling up OnkoNetwork to other regional cen-
tres (i.e. county hospitals with complex oncology care) is
on the political agenda in Hungary.
Workforce
OnkoNetwork introduced new professional roles and
reshaped existing ones as overviewed below.
Changes in the roles of department physicians
Before OnkoNetwork, the organization of diagnostics
was a time consuming and stressful administrative bur-
den on physicians who had to fight for early visit dates
for their patients. OnkoNetwork gave priority status for
patients with suspected cancer throughout the Centre
and passed this organization task to selected department
administrators. Department physicians allocate their
spared hours to more extensive patient communication,
to the treatment of more patients in a day, or to other
professional tasks. On the other hand, the programme
limited the independence of physicians and forced them
Fig. 2 Core features of OnkoNetwork, as opposed to the routine practice in Hungary. TB, Tumour Board
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to collaborate with each other along personalized multi-
disciplinary diagnostic and treatment plans. To ensure
the continuity of care, all enrolled patients have a named
responsible physician who is competent to decide on
their diagnostic tests and is responsible for any delay in
diagnosis and therapy initiation. The responsible phys-
ician changes over time in the patient path: is typically a
physician from the relevant organ-specific department in
the diagnostic phase, a surgeon in the perioperative
stage, and an oncologist during chemo- and radiotherapy
episodes. The responsible physician must be available for
discussions with supervisor physicians, and is also avail-
able for departmental OnkoNetwork administrators, but
shall not be contacted by OnkoNetwork Office adminis-
trators (see the description of these new roles below).
Changes in the roles of departmental non-physician
staff members
One to three assistants or administrators have been se-
lected, appointed and trained in the relevant departments
of the Hospital to become departmental OnkoNetwork
administrators. Their related tasks are 1) case finding, i.e.
to invite and enrol candidate patients from the target
population; 2) to fill in the OnkoNetwork questionnaire at
programme entry based on a patient’s interview; 3) to
schedule visits for protocol driven and responsible phys-
ician initiated diagnostic tests; 4) to record data into
OncoLogistic, including the responsible physician’s ex-
planation for any delay or deviation from the protocol;
and 5) to monitor therapy initiation after the Tumour
Board decision. Most OnkoNetwork administrators in the
departments received their new roles on top of existing
ones, except for departments with highest enrolment rates
where the OnkoNetwork administrator function can be a
full-time position.
A new non-physician role: OnkoNetwork office administrators
In contrast to departmental OnkoNetwork administrators
described in the previous section, OnkoNetwork Office
administrators do not belong to any hospital department.
Interestingly, most OnkoNetwork Office Administrators
did not have prior education or experience in healthcare
service provision but were hired based on their good
organization and communication skills. Their main role is
monitoring and managing patient pathways directly and
through contacts with OnkoNetwork administrators in
linked departments, as supported by the tailored IT appli-
cation OncoLogistic. In a typical day, OnkoNetwork Of-
fice administrators identify about 40–50 OnkoNetwork
candidate patients based on their recorded ICD codes,
and systematically check whether they are invited and en-
rolled into OnkoNetwork by the departmental OnkoNet-
work administrators. They also look after all enrolled
patients with a delay in their pathway on a daily basis.
When they identify a patient with an apparent delay, they
first clarify whether it is due to missing data transfer
across medical IT systems. If not, they turn to the Onko-
Network administrator(s) of the relevant department for
clarification. They always accept the received justification
but secure that it is recorded in OncoLogistic. OnkoNet-
work Office administrators notify the supervisor physi-
cians (see below) about any unsolved issue.
A new physician role: Supervisor physicians
One supervisor physician is working at the Hospital and
another one at the Kaposvár University Health Centre.
Their primary role is to negotiate those OnkoNetwork
related issues with department physicians that could not
solved at the non-physician level. Any remaining un-
solved cases are referred to the Strategic Director of the
Hospital on a weekly basis. The supervisor physicians do
not interfere with medical decisions of department physi-
cians, but request justification for unexplained delays in
diagnostics and care. The selected supervisors have a calm
and helpful personality that efficiently relieves the psycho-
logic stress on the involved non-physician team members.
Barriers and success factors for the new roles
Since no relevant prior experience could be identified in
Hungary, the workflow description and the definition of
new professional roles were started from scratch. Involve-
ment of all stakeholders in the planning, and building con-
sensus agreements were important success factors in the
planning phase. Training for the new roles included inter-
active plenary lectures and practice oriented technical pre-
sentations on model objectives and workflows. Written
guidance to the custom IT tool OncoLogistic was also dis-
tributed, but its technical language could not be easily
understood by several staff members. However, a few
months of learning by doing experience was sufficient for
all administrators to get fluent in OncoLogistic.
At implementation, some surgeons were irritated as
they could not make independent decisions on the treat-
ment (e.g. when to take a histology sample). Their resist-
ance was overcome by the involvement of department
heads in consensus agreements, strong commitment of
the management, and early perceived benefits of the
model, e.g. scheduling the diagnostic visits by OnkoNet-
work administrators. A further barrier came from the
culture of many physicians who were not prepared for
the new professional roles of non-physician colleagues.
OnkoNetwork did not change this attitude of physicians
but circumvented this situation by the establishment of
the supervisor physician role in the model. Supervisor
physicians are much more accepted than non-physician
team members as partners by physicians.
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Relationships with other providers
In Hungary, patients with more complex medical needs
have long waitlists to their definitive care even within a
single institution [4, 5]. Accordingly, key opinion leaders
of OnkoNetwork decided to focus first on the integra-
tion of care processes that were under their control in
the region, i.e. hospital care and secondary outpatient
care provision. Nevertheless, they recognized that inte-
grated care should cover the holistic needs of patients
including prevention, primary healthcare, social care,
psychological support, physiotherapy and dietary advice.
The OnkoNetwork Management identified primary care
and cancer screening programmes as key contributors to
early detection of suspected cancer. Note that cancer
screening programmes in Hungary are organized by
special health promotion offices, without data linkage to
oncology centres and without follow-up system of the
identified positive screening cases. Regional integration of
OnkoNetwork with cancer screening programmes is an
important ambition of the OnkoNetwork management.
Technologies and medical products
Before OnkoNetwork, a range of ICT applications had
already been implemented in the hosting institutions.
The goal of OnkoNetwork was not to replace these IT
systems, but to develop a new tailor-made IT application
(OncoLogistic) in parallel with these systems, to support
documentation and management of patient care path-
ways, and performance monitoring of OnkoNetwork.
Every OncoLogistic user has a personal ID to log in, and
all data entries can be traced back to users. Standardized,
organ-specific diagnostic algorithms are integrated into
OncoLogistic so that the scheduling of diagnostics could
be passed to non-physician users using this platform. Pa-
tients have no access to OncoLogistic at present.
The biggest challenge in the IT development was to
achieve the connectivity of OncoLogistic to existing
medical IT systems. The key issue with data transfer
across IT systems was the lack of appropriate medical IT
standards. On one hand, diagnosis-related-groups and
intervention codes had been created only for financial
purposes in Hungary and are not sufficiently graded to
differentiate between disease and intervention subtypes in
patient pathway algorithms. On the other hand, independ-
ent IT software developments resulted in a multitude of
medical IT applications that are in use at different pro-
viders but are not compatible with each other.
Differences in professional languages, terms and ways of
thinking occasionally also resulted in barriers when the
development of diagnostic algorithms was approached by
clinicians and IT engineers. A mediator with thorough ex-
perience in both disciplines, and the openness of upper
management to IT perspectives could facilitate resolution
in such situations.
Development of OncoLogistic was a big technical chal-
lenge as shown above, however, this tailor-made IT ap-
plication after its launch became an important success
factor in the implementation of OnkoNetwork, empow-
ering the relevant stakeholders with up-to-date reports,
and organizing their daily work on a well-documented
and transparent platform.
Departmental OnkoNetwork administrators entered
data both into OncoLogistic and into the hospital’s med-
ical system in parallel, due to the limitations of the
established interface between these systems (a pilot up-
date version of OnkoNetwork with improved connectiv-
ity was under development). Data export / import in
OncoLogistic was under continuous fine-tuning. An-
other development direction for OncoLogistic was the
integration of treatment algorithms. Future development
opportunities for OncoLogistic include building inter-
faces to all healthcare IT systems in Hungary, and its re-
gional scale-up in Hungary and beyond. This tool was
developed in a way that allows its rapid adaptation to
other regions / healthcare systems, and it is multilingual,
theoretically capable to import data from any system.
Information and research
No formal evaluation reports on OnkoNetwork are
available so far. The management expects that at least a
few years of follow-up will be necessary to evaluate its
clinical and economic impacts. Moreover, benefits of the
programme are expected to be boosted once the cancer
screening system and primary care will be connected,
shortening the patient delay before first secondary care
visit. Dimensions of the expected impact of OnkoNet-
work are summarized below, along with the currently
available very limited data on timeliness of care.
Clinical outcomes
Initial analyses suggest shortened timelines for diagnosis and
treatment initiation, as expected. The mean time from initial
indicative diagnosis in the hospital to Tumour Board meet-
ing is reported to be 21–22 days in OnkoNetwork with a
standard deviation of 14 days. Before OnkoNetwork, the
mean duration was 64 days with a standard deviation of 40
days in the Hospital. For comparison, the mean duration of
cancer diagnosis in other Hungarian hospitals can be as high
as 110 days [12].The interviewees expected that OnkoNet-
work will result in better patient compliance in the diagnostic
phase, less incentives for patients to visit private healthcare
providers in order to speed up the diagnostic process, faster
diagnosis and treatment of comorbidities, lower frequency of
inconclusive Tumour Board meetings, earlier start of treat-
ment, lower proportion of patients with cancer metastases at
diagnosis, longer patient survival, and/or better nutritional
status of patients with head-neck tumours during therapy.
Some interview participants suggested that more patients
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would receive surgical care due to a shift in cancer stage dis-
tribution at diagnosis towards less progressed cases, while
the opposite expectation was also mentioned referring to the
decreasing dominance of surgeons in multidisciplinary treat-
ment decisions. Future evaluation of clinical outcomes will
be facilitated by the ongoing patient-level data collection in
OncoLogistic since the completeness, timeliness, and face
validity of the entered data is monitored and assured by the
OnkoNetwork Office.
Patient experience
The interviewees expected that OnkoNetwork will result
in improved patient experience, since OnkoNetwork al-
lows more time for physicians to communicate with their
patients, the waiting lists are getting shorter, patients experi-
ence less need for travel and shorter waiting times on the
day of diagnostics, and the number of patients intending to
get enrolled outside from the catchment area of OnkoNet-
work has recently increased. However, it was also noted that
patients probably cannot link their fairly positive healthcare
experience to the OnkoNetwork model, as fortunately they
usually do not have relevant personal benchmarks in cancer
care. Current monitoring of patient experience is restricted
to the collection of anonymous patient satisfaction surveys
that are evaluated at the department level and can’t be
linked with the patients’ OnkoNetwork enrolment status.
Economic aspects
No economic analyses of OnkoNetwork have been con-
ducted so far. From the perspective of the Centre, no
significant economic impact is expected. The current
running and operating costs of OnkoNetwork are lim-
ited to the human resources cost of about 4 full-time
employees and the office leader in the OnkoNetwork Of-
fice. In general, no change is expected in the number of
diagnostic visits: the number of outpatient visits per pa-
tient is expected to decrease, but this decrease is be-
lieved to be compensated for by slightly higher patient
turnover. In contrast, significant economic benefits are
expected to occur at the level of the national healthcare
payer and the society due to a shift of the cancer stage
distribution towards less advanced stages, enabling earl-
ier and therefore less expensive treatment and better
clinical outcomes.
Financing
Project financing
OnkoNetwork is a regional initiative without a specific
macro-level payment scheme / incentive system around
it, except for a prior financial support from EU funds for
the development of OncoLogistic [21]. All running and
operating costs of the model are funded from regular in-
patient and outpatient financing sources received from
the national healthcare payer. The National Healthcare
Services Center (ÁEEK), which is a governmental insti-
tute in charge of state ownership rights at the majority
of hospitals in Hungary, is aware of the programme and
has recently rewarded it [22]. However, no additional
central funds were provided for the maintenance or de-
velopment of OnkoNetwork. It is unclear whether finan-
cial incentives for the management of patient pathways
will be established in the Hungarian healthcare financing
system in the future.
Although the intellectual property rights of OnkoNet-
work belong to the General Director of the Hospital, she
considers it as a public good to improve the Hungarian
healthcare system. Hence, it is available for extension to
other regions subject to a financial contribution to invest-
ments in the initial and further development of the system.
Personal incentives
OnkoNetwork administrators of the departments and
supervisor physicians typically took up the new roles on
top of their existing responsibilities and tasks without
significant incremental financial compensation for their
additional workload. Instead, staff members reported
other motivating factors, including 1) participation in an
innovative and patient-oriented model, 2) working in
well-designed hospital buildings with modern infrastruc-
ture, such as dedicated workstations with personal com-
puters, 3) open communication at project meetings, 4)
positive behaviour of the supervisor physicians, 5) infor-
mal social events e.g. birthday parties, and 6) the per-
ceived improvement in individual patient pathways.
Coordinators of pathways expressed that they considered
the monitored patients almost as their family members
and achieving optimal patient care provided personal
satisfaction to themselves. Supervisor physicians were
motivated by the importance of this pioneering initiative
in the Hungarian healthcare setting, and by the imma-
terial appreciation from the colleagues and programme
management. The management of OnkoNetwork ac-
knowledges that healthcare administrators have a par-
ticularly low salary in Hungary by law, and definitely
more compensation would be needed for them. In gen-
eral, salaries in the Hungarian healthcare system are
thought to be disappointingly low.
Discussion
This paper provides a systematic description of planning,
implementation and operation of the OnkoNetwork
model programme, based on document analysis and in-
terviews with programme initiators, managers, financial
manager, involved physician and non-physician profes-
sionals, patients and their informal caregivers. OnkoNet-
work was established in 2014 by the Móritz Kaposi
General Hospital in Somogy county, Hungary with the
aims of timely, continuous, and quality assured care of
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patients with first suspect of solid organ cancer in the
catchment area of the participating institutions. Comorbidi-
ties frequently occur in cancer patients and need to be
stabilized for optimal cancer treatment, qualifying Onko-
Network for evaluation in the multimorbidity focused
SELFIE project. OnkoNetwork has highly innovative ap-
proaches in its context (new professional roles and work-
flows, a supporting custom IT platform). The model is
financially sustainable without receiving macro-level finan-
cial incentives for its operation at present. Its realized im-
pacts on patient experience, health, and resource utilization
is currently being investigated, with first results expected in
late 2018.
Providing timely and continuous care to patients with
suspected cancer need to be improved even in countries
with most developed health systems. The 2015 National
Cancer Program in Sweden standardized the cancer care
pathways and specified time bounds for its various inter-
vals starting from the event of “well-founded suspicion”
which is defined separately for each cancer type. The ob-
jective of the Swedish initiative was to reduce waiting
times, increase patient satisfaction and reduce regional
inequalities in Sweden where cancer patients have gener-
ally high survival rates as compared with other EU
member States [23]. In Denmark, a three-legged strategy
was proposed for timely cancer diagnosis by urgent re-
ferral of patients with cancer specific symptoms and pa-
tients with unspecific but serious symptoms, and by
setting up easy and fast access to “No-Yes-Clinics” or
Multi-Disciplinary Diagnostic Centres for patients with
common and non-serious symptoms raising a potential
cancer diagnosis [24]. The UK government introduced
the ‘Cancer waiting times targets’ as part of the NHS
Cancer Plan in 2000, stipulating that patients with sus-
pected cancer should be seen by a specialist within 14
days and treated within 48 days. The overall time from
referral with suspected cancer to diagnosis and starting
treatment should not exceed 62 days [25]. Timely cancer
diagnosis in patients with unspecific symptoms is also in
the forefront of research interest in the UK, where the
Cancer Task Force Strategy for England considers the
introduction of similar multidisciplinary centres to those
established in Denmark [26]. Expecting improved stage
distribution at diagnosis and patient survival by the
timely diagnosis and treatment of suspected cancer pa-
tients is plausible when long delays occur in patient
paths, but this assumption still calls for convincing evi-
dence in many cancer types – sometimes with equivocal
or even negative association findings due to various
sources of bias, including the wait time paradox or ad-
justment to factors in the causal chains [27, 28]. The on-
going performance assessment of OnkoNetwork on a
comprehensive range of patient health, experience, and re-
source utilization outcomes will meaningfully contribute
to the ongoing scientific debate, providing new evidence
from a former socialist EU Member State with less devel-
oped health system and with larger room for improvement
in providing timely care for patients with cancer suspect.
Notably, in a recently completed EU-funded project
(ICARE4EU) overviewing 101 integrated care programmes
throughout the geographical Europe, only 16% of the rele-
vant models were identified in former socialist EU Member
States, and no programme could be included from the Vise-
grád group countries (Czech Republic, Hungary, Poland,
Slovakia) and Estonia [29]. This geographic disparity in inte-
grated care models is particularly disconcerting when differ-
ences in healthcare and social systems, economic, legal, and
cultural contexts, as well as expected life years or health out-
comes are considered between these regions and EU-15
Member States. Given that integrated care models are de-
signed to fit to their surrounding macro-level environment,
the transferability of experience accumulating in Western
European countries to former socialist EU Member States
need to be carefully assessed.
Beyond the qualitative study reported in this paper, the
SELFIE project makes additional important steps to
close the knowledge gap between the EU-15 and newer
Member States. First, thick descriptions of three further
chronic integrated care models for multimorbid patients
have been approached in the CEU region, one more in
Hungary [30] and two in Croatia [31, 32]. In addition,
transferability assessment of 13 promising integrated
care models from Western EU partner countries to CEE
Member States, together with their financing/payment
schemes and performance monitoring tools is specific-
ally addressed in a dedicated work package of SELFIE.
The anticipated knowledge transfer of best available
European practices to less developed Member States
with lower research capacity is an important opportunity
in SELFIE, highlighting the significance of EU-funded re-
search that facilitates knowledge sharing across countries
and stimulates more extensive international research
collaborations [2].
An inherent limitation of our study is determined by
its qualitative design - the present research could not
quantify the added value of OnkoNetwork to the sur-
rounding healthcare system in Hungary. However, the
conducted document analysis and stakeholder interviews
allowed us to understand how OnkoNewtork was ini-
tially conceptualized and implemented, and how it could
change the healthcare service provision practice in a
comprehensive oncology care centre. The in-depth under-
standing of various stakeholder perspectives, facilitators
and barriers empower the reader to learn from a carefully
planned, regional initiative for timely and integrated care
that turned to be implementable and sustainable in the
healthcare system of a CEE Member State. Existing data
on the quantitative impact of OnkoNetwork is marginal at
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present, due to the short duration of time since its initi-
ation. In stakeholder interviews, an impressive list of per-
ceived or expected impacts was gathered along the triple
aim of improving i) population health (e.g. faster diagnosis
and treatment of cancer and interfering comorbidities, im-
proved patient compliance with diagnostics and treatment,
better stage distribution at start of cancer treatment, better
nutritional status of patients with head-neck tumours dur-
ing therapy, and longer patient survival); ii) patient experi-
ence (e.g. shorter waitlists, more time for patient-physician
communication, improved continuity of care); and iii) redu-
cing the costs or growth in costs where significant economic
benefits are expected to occur at the national healthcare
payer and the society due to a shift of the cancer stage dis-
tribution towards less advanced stages. The perceived im-
pacts promise more effective and cost-effective care for
oncology patients with better physical functioning and psy-
chological well-being. Designing a thorough quantitative
study of the impact of OnkoNetwork on clinical outcomes,
patient experience, and healthcare costs was guided by the
findings of this qualitative study. The quantitative evalu-
ation of OnkoNetwork is ongoing, first results are expected
in late 2018.
Conclusions
Although integrated care is in the forefront of health pol-
icy research in the EU, very few integrated care models are
reported from former socialist EU Member States. Given
that integrated care models are designed to fit to their spe-
cific context in the hosting country, those few models that
were established in CEE countries and are sustainable rep-
resent important benchmarks for further models in this
region. The comprehensive description of planning, im-
plementation and operation of OnkoNetwork with its key
success factors and barriers may support the development
of new integrated care models especially in CEE countries.
Findings of our study on the expected impacts of Onko-
Network guided the planning of a subsequent quantitative
study that is currently ongoing and will meaningfully con-
tribute to the ongoing international debate on benefits as-
sociated with timeliness of cancer care.
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